Immunogenicity of SARS-CoV-2 BNT162b2 vaccine in solid organ transplant recipients

Smaragdi Marinaki; Stamatis Adamopoulos; Dimitrios Degiannis; Sotirios Roussos; Ioanna D Pavlopoulou; Angelos Hatzakis; Ioannis N Boletis

doi:10.1111/ajt.16607

Immunogenicity of SARS-CoV-2 BNT162b2 vaccine in solid organ transplant recipients

Am J Transplant. 2021 Aug;21(8):2913-2915. doi: 10.1111/ajt.16607. Epub 2021 May 7.

Authors

Smaragdi Marinaki¹, Stamatis Adamopoulos², Dimitrios Degiannis³, Sotirios Roussos⁴, Ioanna D Pavlopoulou⁵, Angelos Hatzakis⁶, Ioannis N Boletis¹

Affiliations

¹ Clinic of Nephrology and Renal Transplantation NKUA, Medical School, Laiko General Hospital, Athens, Greece.
² Heart Failure and Transplant Units, Onassis Cardiac Surgery Center, Athens, Greece.
³ Molecular Immunopathology and Histocompatibility Unit, Onassis Cardiac Surgery Center, Athens, Greece.
⁴ Department of Hygiene, Epidemiology and Medical Statistics NKUA, Medical School, Athens, Greece.
⁵ Pediatric Research Laboratory, Faculty of Nursing, NKUA, School of Health Sciences, Athens, Greece.
⁶ Hellenic Scientific Society for the Study of AIDS, Sexually Transmitted and Emerging Diseases, Athens, Greece.

No abstract available

Keywords: clinical research/practice; heart transplantation/cardiology; infection and infectious agents - viral; infectious disease; kidney transplantation/nephrology; vaccine.

Publication types

Letter

MeSH terms

BNT162 Vaccine
COVID-19 Vaccines
COVID-19*
Humans
Organ Transplantation*
SARS-CoV-2
Transplant Recipients

Substances

COVID-19 Vaccines
BNT162 Vaccine

Grants and funding

704/13.01.2021/Onassis Cardiac Surgery Center